Need for a standardized translational drug development platform: lessons learned from the repurposing of drugs for COVID-19

In the absence of drugs to treat or prevent COVID-19, drug repurposing can be a valuable strategy. Despite a substantial number of clinical trials, drug repurposing did not deliver on its promise. While success was observed with some repurposed drugs (e.g., remdesivir, dexamethasone, tocilizumab, ba...

Full description

Bibliographic Details
Main Authors:	Assmus, F, Driouich, J-S, Abdelnabi, R, Vangeel, L, Touret, F, Adehin, A, Chotsiri, P, Cochin, M, Foo, CS, Jochmans, D, Kim, S, Luciani, L, Moureau, G, Park, S, Pétit, P-R, Shum, D, Wattanakul, T, Weynand, B, Fraisse, L, Ioset, J-R, Mowbray, CE, Owen, A, Hoglund, RM, Tarning, J, Lamballerie, XD, Nougairède, A, Neyts, J, Sjö, P, Escudié, F, Scandale, I, Chatelain, E
Format:	Journal article
Language:	English
Published:	MDPI 2022

Need for a standardized translational drug development platform: lessons learned from the repurposing of drugs for COVID-19

Similar Items